Martina Brueckmann

24.5k total citations · 6 hit papers
147 papers, 7.0k citations indexed

About

Martina Brueckmann is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Martina Brueckmann has authored 147 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 91 papers in Cardiology and Cardiovascular Medicine, 71 papers in Endocrinology, Diabetes and Metabolism and 46 papers in Surgery. Recurrent topics in Martina Brueckmann's work include Diabetes Treatment and Management (66 papers), Heart Failure Treatment and Management (40 papers) and Pancreatic function and diabetes (37 papers). Martina Brueckmann is often cited by papers focused on Diabetes Treatment and Management (66 papers), Heart Failure Treatment and Management (40 papers) and Pancreatic function and diabetes (37 papers). Martina Brueckmann collaborates with scholars based in Germany, United States and United Kingdom. Martina Brueckmann's co-authors include João Pedro Ferreira, Milton Packer, Faı̈ez Zannad, Gerasimos Filippatos, Stuart Pocock, Javed Butler, Stefan D. Anker, Waheed Jamal, Anne Pernille Ofstad and Ursula Hoffmann and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Martina Brueckmann

143 papers receiving 6.8k citations

Hit Papers

Dabigatran versus Warfari... 2013 2026 2017 2021 2013 2020 2020 2020 2021 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dabigatran versus Warfarin in Patients with Mechanical Heart Valves
    2013 948 citations Martina Brueckmann, Christopher B. Granger et al. profile →
  2. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
    2020 831 citations Faı̈ez Zannad, João Pedro Ferreira et al. profile →
  3. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction
    2020 266 citations Milton Packer, Stefan D. Anker et al. Circulation profile →
  4. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status
    2020 243 citations Stefan D. Anker, Javed Butler et al. Circulation profile →
  5. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction
    2021 159 citations Javed Butler, Milton Packer et al. European Heart Journal profile →
  6. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial
    2022 119 citations Jan Biegus, Adriaan A. Voors et al. European Heart Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Martina Brueckmann Germany 40 4.4k 2.6k 1.5k 1.3k 1.1k 147 7.0k
Koichi Kaikita Japan 41 3.8k 0.9× 806 0.3× 1.4k 1.0× 662 0.5× 596 0.5× 308 6.9k
Greg C. Flaker United States 35 9.0k 2.1× 1.0k 0.4× 2.5k 1.7× 755 0.6× 1.1k 1.0× 79 10.5k
Holger Reinecke Germany 35 2.2k 0.5× 466 0.2× 1.7k 1.2× 1.2k 0.9× 919 0.8× 231 4.9k
Tohru Masuyama Japan 43 5.7k 1.3× 640 0.2× 2.3k 1.6× 1.3k 1.0× 456 0.4× 304 8.3k
Amir Halkin Israel 39 4.1k 0.9× 385 0.1× 1.7k 1.1× 1.2k 0.9× 859 0.7× 135 6.0k
Katsumi Miyauchi Japan 38 2.9k 0.7× 960 0.4× 2.8k 1.9× 653 0.5× 634 0.6× 303 6.2k
Vincenzo Pasceri Italy 41 4.8k 1.1× 527 0.2× 3.6k 2.4× 737 0.6× 1.4k 1.3× 131 8.3k
Brendan M. Everett United States 36 2.2k 0.5× 1.6k 0.6× 1.6k 1.1× 403 0.3× 760 0.7× 91 5.2k
Siegmund Braun Germany 40 3.5k 0.8× 466 0.2× 2.1k 1.4× 671 0.5× 679 0.6× 128 6.8k
Anetta Undas Poland 40 2.2k 0.5× 566 0.2× 1.4k 1.0× 1.9k 1.5× 1.1k 1.0× 282 6.3k

Countries citing papers authored by Martina Brueckmann

Since Specialization
Citations

This map shows the geographic impact of Martina Brueckmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martina Brueckmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martina Brueckmann more than expected).

Fields of papers citing papers by Martina Brueckmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martina Brueckmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martina Brueckmann. The network helps show where Martina Brueckmann may publish in the future.

Co-authorship network of co-authors of Martina Brueckmann

This figure shows the co-authorship network connecting the top 25 collaborators of Martina Brueckmann. A scholar is included among the top collaborators of Martina Brueckmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martina Brueckmann. Martina Brueckmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Roux, Carel W. le, Sean Wharton, Biykem Bozkurt, et al.. (2025). Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial ( SYNCHRONIZE ™‐1). Diabetes Obesity and Metabolism. 28(1). 337–346.
2.
Böhm, Michael, Javed Butler, Andrew J.S. Coats, et al.. (2025). Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. European Heart Journal. 46(14). 1304–1317. 9 indexed citations
3.
Haertter, Sebastian, et al.. (2024). Clinical pharmacokinetics and pharmacodynamics of empagliflozin in patients with heart failure. British Journal of Clinical Pharmacology. 90(9). 2215–2222. 1 indexed citations
4.
Sattar, Naveed, Javed Butler, Matthew M.Y. Lee, et al.. (2024). Body Mass Index and Cardiorenal Outcomes in the EMPEROR-Preserved Trial: Principal Findings and Meta-Analysis with the DELIVER Trial. European Journal of Heart Failure. 26(4). 900–909. 15 indexed citations
5.
Albisetti, Manuela, Igor Tartakovsky, Jacqueline Halton, et al.. (2024). Dabigatran for Treatment and Secondary Prevention of Venous Thromboembolism in Pediatric Congenital Heart Disease. Journal of the American Heart Association. 13(4). e028957–e028957. 4 indexed citations
6.
Ferreira, João Pedro, Jon Blatchford, John R. Teerlink, et al.. (2023). Mineralocorticoid Receptor Antagonist Use and the Effects of Empagliflozin on Clinical Outcomes in Patients Admitted for Acute Heart Failure: Findings from EMPULSE. European Journal of Heart Failure. 25(10). 1797–1805. 6 indexed citations
7.
Butler, Javed, Milton Packer, Tariq Jamal Siddiqi, et al.. (2023). Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories. Journal of the American College of Cardiology. 81(19). 1902–1914. 20 indexed citations
8.
Böhm, Michael, Javed Butler, Marcin Krawczyk, et al.. (2023). Liver Tests, Cardiovascular Outcomes and Effects of Empagliflozin in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. European Journal of Heart Failure. 25(8). 1375–1383. 12 indexed citations
9.
Kosiborod, Mikhail, Christiane E. Angermann, Sean P. Collins, et al.. (2022). Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. Circulation. 146(4). 279–288. 93 indexed citations
10.
Böhm, Michael, Javed Butler, Gerasimos Filippatos, et al.. (2022). Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age. Journal of the American College of Cardiology. 80(1). 1–18. 39 indexed citations
11.
Brutto, Víctor J. Del, Hans‐Christoph Diener, J. Donald Easton, et al.. (2022). Predictors of Recurrent Stroke After Embolic Stroke of Undetermined Source in the RE‐SPECT ESUS Trial. Journal of the American Heart Association. 11(11). e023545–e023545. 8 indexed citations
12.
Böhm, Michael, Stefan D. Anker, Felix Mahfoud, et al.. (2022). Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. European Heart Journal. 44(5). 396–407. 31 indexed citations
13.
Albisetti, Manuela, Igor Tartakovsky, Jacqueline Halton, et al.. (2021). Abstract 9192: Efficacy and Safety of Dabigatran in the Treatment and Secondary Prophylaxis of Children With Congenital Heart Disease. Circulation. 144(Suppl_1). 1 indexed citations
14.
Uchiyama, Shinichiro, Ḱazunori Toyoda, Byung‐Chul Lee, et al.. (2021). Dabigatran or Aspirin in East Asian Patients With Embolic Stroke of Undetermined Source. Stroke. 52(3). 1069–1073. 5 indexed citations
15.
Packer, Milton, Javed Butler, Gerasimos Filippatos, et al.. (2020). Design of a Prospective Patient-Level Pooled Analysis of Two Parallel Trials of Empagliflozin in Patients with Established Heart Failure. European Journal of Heart Failure. 22(12). 2393–2398. 18 indexed citations
16.
Brandão, Leonardo R., Manuela Albisetti, Lisa Bomgaars, et al.. (2019). Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. Blood. 135(7). 491–504. 64 indexed citations
17.
18.
Samama, Charles Marc, Nadia Rosencher, Eva Kleine, et al.. (2016). Observational study of dabigatran etexilate 150 mg in patients with moderate renal impairment undergoing elective total hip or knee replacement. Thrombosis Research. 143. 103–110. 4 indexed citations
19.
Behnes, Michael, Martina Brueckmann, Siegfried Lang, et al.. (2013). Diagnostic and Prognostic Value of Osteopontin in Patients with Acute Congestive Heart Failure. European Journal of Heart Failure. 15(12). 1390–1400. 25 indexed citations
20.
Behnes, Michael, Martina Brueckmann, Siegfried Lang, et al.. (2008). Time-course of neopterin levels in patients suffering from severe sepsis treated with and without Drotrecogin-alpha (activated). Scandinavian Journal of Infectious Diseases. 40(6-7). 503–508. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Koichi Kaikita Breakdown of academic impact, for papers by Greg C. Flaker Breakdown of academic impact, for papers by Holger Reinecke Breakdown of academic impact, for papers by Tohru Masuyama Breakdown of academic impact, for papers by Amir Halkin Breakdown of academic impact, for papers by Katsumi Miyauchi Breakdown of academic impact, for papers by Vincenzo Pasceri Breakdown of academic impact, for papers by Brendan M. Everett Breakdown of academic impact, for papers by Siegmund Braun Breakdown of academic impact, for papers by Anetta Undas
Rankless by CCL
2026